These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 2018816)

  • 1. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder.
    Pigott TA; Zohar J; Hill JL; Bernstein SE; Grover GN; Zohar-Kadouch RC; Murphy DL
    Biol Psychiatry; 1991 Mar; 29(5):418-26. PubMed ID: 2018816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results.
    Broocks A; Pigott TA; Hill JL; Canter S; Grady TA; L'Heureux F; Murphy DL
    Psychiatry Res; 1998 Jun; 79(1):11-20. PubMed ID: 9676822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP.
    Pigott TA; Hill JL; Grady TA; L'Heureux F; Bernstein S; Rubenstein CS; Murphy DL
    Biol Psychiatry; 1993 Jan; 33(1):3-14. PubMed ID: 8420593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans.
    Mueller EA; Murphy DL; Sunderland T
    Psychopharmacology (Berl); 1986; 89(3):388-91. PubMed ID: 3014595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.
    Hollander E; DeCaria CM; Nitescu A; Gully R; Suckow RF; Cooper TB; Gorman JM; Klein DF; Liebowitz MR
    Arch Gen Psychiatry; 1992 Jan; 49(1):21-8. PubMed ID: 1728249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action.
    Benkelfat C; Murphy DL; Zohar J; Hill JL; Grover G; Insel TR
    Arch Gen Psychiatry; 1989 Jan; 46(1):23-8. PubMed ID: 2910220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology.
    Zohar J; Insel TR
    Biol Psychiatry; 1987 Jun; 22(6):667-87. PubMed ID: 3036259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls.
    Zohar J; Mueller EA; Insel TR; Zohar-Kadouch RC; Murphy DL
    Arch Gen Psychiatry; 1987 Nov; 44(11):946-51. PubMed ID: 3675134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder.
    Khanna S; John JP; Reddy LP
    Psychoneuroendocrinology; 2001 Feb; 26(2):209-23. PubMed ID: 11087965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.
    Charney DS; Goodman WK; Price LH; Woods SW; Rasmussen SA; Heninger GR
    Arch Gen Psychiatry; 1988 Feb; 45(2):177-85. PubMed ID: 3337615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation.
    Goodman WK; McDougle CJ; Price LH; Barr LC; Hills OF; Caplik JF; Charney DS; Heninger GR
    Biol Psychiatry; 1995 Aug; 38(3):138-49. PubMed ID: 7578657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder.
    Hollander E; DeCaria C; Gully R; Nitescu A; Suckow RF; Gorman JM; Klein DF; Liebowitz MR
    Psychiatry Res; 1991 Jan; 36(1):1-17. PubMed ID: 2017519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects.
    Klein E; Zohar J; Geraci MF; Murphy DL; Uhde TW
    Biol Psychiatry; 1991 Nov; 30(10):973-84. PubMed ID: 1756202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan.
    Gross-Isseroff R; Cohen R; Sasson Y; Voet H; Zohar J
    Neuropsychobiology; 2004; 50(3):200-5. PubMed ID: 15365215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo.
    de Leeuw AS; Westenberg HG
    J Psychiatr Res; 2008 Sep; 42(11):894-901. PubMed ID: 18533183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obsessive-compulsive disorder as a 5-HT subsystem-related behavioural disorder.
    Murphy DL; Zohar J; Benkelfat C; Pato MT; Pigott TA; Insel TR
    Br J Psychiatry Suppl; 1989 Dec; (8):15-24. PubMed ID: 2692636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder.
    Bastani B; Nash JF; Meltzer HY
    Arch Gen Psychiatry; 1990 Sep; 47(9):833-9. PubMed ID: 2203327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects.
    Kahn RS; Kalus O; Wetzler S; Cahn W; Asnis GM; van Praag HM
    Psychiatry Res; 1990 Aug; 33(2):189-98. PubMed ID: 2243896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of various serotonin receptor subtype-selective antagonists alone and on m-chlorophenylpiperazine-induced neuroendocrine changes in rats.
    Aulakh CS; Hill JL; Murphy DL
    J Pharmacol Exp Ther; 1992 Nov; 263(2):588-95. PubMed ID: 1432690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonergic function in social phobia: comparison to normal control and obsessive-compulsive disorder subjects.
    Hollander E; Kwon J; Weiller F; Cohen L; Stein DJ; DeCaria C; Liebowitz M; Simeon D
    Psychiatry Res; 1998 Jul; 79(3):213-7. PubMed ID: 9704868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.